Delving into the Latest Updates on Salmonella paratyphi A conjugate vaccine (Royal (Wuxi) Bio-Pharm) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Conjugated vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication

Paratyphoid A feverTyphoid Fever

Inactive Indication-

Originator Organization

Royal (Wuxi) Bio-Pharmaceutical Co., Ltd.

Active Organization

Royal (Wuxi) Bio-Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Through Phase I clinical trials, the safety and tolerability of the Typhoid A and Paratyphoid conjugate vaccine developed by Luoyi (Wuxi) Biopharmaceutical Co., Ltd. after immunization in healthy people over 6 months old in China were evaluated, and the immunogenicity was preliminarily explored, laying the foundation for Phase II and Phase III clinical studies.

Start Date-

Sponsor / Collaborator

Royal (Wuxi) Bio-Pharmaceutical Co., Ltd.

100 Clinical Results associated with Salmonella paratyphi A conjugate vaccine (Royal (Wuxi) Bio-Pharm)

Login to view more data

100 Translational Medicine associated with Salmonella paratyphi A conjugate vaccine (Royal (Wuxi) Bio-Pharm)

Login to view more data

100 Patents (Medical) associated with Salmonella paratyphi A conjugate vaccine (Royal (Wuxi) Bio-Pharm)

Login to view more data

100 Deals associated with Salmonella paratyphi A conjugate vaccine (Royal (Wuxi) Bio-Pharm)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Paratyphoid A fever	Phase 1	China	Royal (Wuxi) Bio-Pharmaceutical Co., Ltd.	30 May 2018
Typhoid Fever	Phase 1	China	Royal (Wuxi) Bio-Pharmaceutical Co., Ltd.	30 May 2018